Table I.
Baseline patient and treatment characteristics
| Variable | Valuea |
|---|---|
| Patients (n) | 43 |
| Age (years) | |
| Median | 62 |
| Range | 44–78 |
| Mean body surface area | 1.92±0.03 |
| Male sex (%) | 62.3 |
| ecog ps 0 or 1 (%)b | 100 |
| Charlson comorbidity indexc | |
| Median score | 8 |
| Range | 6–13 |
| Mean baseline biochemistry | |
| Hemoglobin (g/L) | 129.3±2.1 |
| While blood cells (×109/L) | 7.1±0.48 |
| Absolute neutrophil count (×109/L) | 6.4±1.50 |
| Platelets (×109/L) | 312±16.6 |
| Urea (mmol/L) | 4.5±0.25 |
| Disease stage and characteristics (%) | |
| Resected stage iv | 7.0 |
| Metastatic | 93.0 |
| Colostomy present | 25.6 |
| Previous pelvic radiation | 42.9 |
| Central venous access present | 83.3 |
| Prior red blood cell transfusions | 62.2 |
| Prior vte | 2.4 |
| Prior adjuvant chemotherapy | 53.5 |
| Current line of chemotherapy | |
| First | 95.4 |
| Second | 4.6 |
| Stool habit at baseline (%) | |
| Grade 1 or 2 diarrhea | 7.0 |
| Constipation | 7.0 |
| Mean absolute dose at cycle 1 (mg) | |
| 5fu bolus | 711±14.0 |
| 5fu continuous infusion | 4223±128 |
| Irinotecan | 321±6.2 |
| Bevacizumab | 390±15.8 |
| Bevacizumab cycle length (%) | |
| Every 2 weeks | 100 |
| Every 3 weeks | 0 |
a
Mean ± standard error, or other value as stated.
b
Eastern Cooperative Oncology Group performance status performance status (ecog ps) could be accurately assessed in only 22 patients.
c
The weighted comorbidity classes were low (0 points), median (1–2 points), high (3–4 points), and very high (≥5 points).
5fu = 5-fluorouracil; vte = venous thromboembolic event.